Skip to main content

Advertisement

SpringerLink
Log in

Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain

  • Research Article
  • Published:
Tumor Biology

Abstract

Assessment of the human epidermal growth factor receptor-2 (Her2/ErbB2) and estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer has been an accepted standard to predict clinical outcome. Expression of these receptors in primary breast cancer has also been an important predictor of visceral organ metastasis. Many studies of breast cancer have reported risk factors for brain metastasis that include Her2/ErbB2 positivity, ER negativity, and negativity for all the above three receptors. However, it is not clear whether expression of these receptors would persist subsequent to brain metastasis. To address this possibility, we analyzed different breast cancer brain metastases (BCBM) for the expression of Her2/ErbB2, ER, and PR by immunohistochemistry procedure. The results showed that BCBM are heterogeneous in the receptor expression: Five BCBMs were Her2/ErbB2-positive and one negative; four BCBMs were ER-positive, and two were negative; five BCBMs were PR-positive and one negative. However, expression of these receptors in their combination is also heterogeneous: Four BCBMs were positive for all of the Her2/ErbB2, ER, and PR; one BCBM was positive for Her2/ErbB2 and PR but negative for ER; one BCBM was positive for PR but negative for Her2/ErbB2/ER. Similar heterogeneity in the expression of these receptors was also observed in primary tumors. Importantly, BCBM tumors that were assigned as ER- and PR-positive contained tumor cells that lacked expression of these receptors in other regions of the biopsies. Taken together, our findings indicate that the BCBM exhibit heterogeneity in the expression amounts of Her2/ErbB2, ER, and PR, which could be a result of the influence of tumor microenvironment in the brain or different tumor cells populating the metastatic region.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.

    Article  PubMed  Google Scholar 

  2. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009;69(12):4951–3. doi:10.1158/0008-5472.CAN-09-0099.

    Article  CAS  PubMed  Google Scholar 

  3. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw : JNCCN. 2009;7(10):1060–96.

    PubMed  Google Scholar 

  4. Rao US, Hoerster NS, Thirumala S, Rao PS. The influence of metastatic site on the expression of CEA and cellular localization of beta-catenin in colorectal cancer. J Gastroenterol Hepatol. 2013;28(3):505–12. doi:10.1111/jgh.12083.

    Article  CAS  PubMed  Google Scholar 

  5. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004;64(9):3037–45.

    Article  CAS  PubMed  Google Scholar 

  6. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res : BCR. 2005;7(4):143–8. doi:10.1186/bcr1041.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Roy S, Gascard P, Dumont N, Zhao J, Pan D, Petrie S, et al. Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proc Natl Acad Sci U S A. 2013;110(12):4598–603. doi:10.1073/pnas.1218682110.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412.

    Article  Google Scholar 

  9. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest. 2014;124(2):859–70. doi:10.1172/JCI70941.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7(10):791–9. doi:10.1038/nrc2212.

    Article  CAS  PubMed  Google Scholar 

  11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28(16):2784–95. doi:10.1200/JCO.2009.25.6529.

    Article  Google Scholar 

  12. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res : BCR. 2004;6(6):240–5. doi:10.1186/bcr938.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.

    Article  Google Scholar 

  14. Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol : Off J Am Soc Clin Oncol. 2004;22(9):1769–70. doi:10.1200/JCO.2004.99.251.

    Article  Google Scholar 

  15. Colozza M, Larsimont D, Piccart MJ. Progesterone receptor testing: not the right time to be buried. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(16):3867–8. doi:10.1200/JCO.2005.05.167. author reply 9-70.

    Article  CAS  Google Scholar 

  16. Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(2):931. doi:10.1200/JCO.2005.05.152. author reply 2-3.

    Article  Google Scholar 

  17. Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res : BCR. 2013;15(4):R68. doi:10.1186/bcr3462.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Gelbfish GA, Davidson AL, Kopel S, Schreibman B, Gelbfish JS, Degenshein GA, et al. Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg. 1988;207(1):75–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor. Adv Exp Med Biol. 1979;117:95–110.

    Article  CAS  PubMed  Google Scholar 

  20. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(2):203–9. doi:10.1200/JCO.2012.43.4134.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The corresponding author wishes to thank President Michael McGlothlin for his interest and support for research program at the institution.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Appalachian College of Pharmacy, 1060 Dragon Rd, Oakwood, VA, 24631, USA

    Prema S. Rao, Morgan Labhart & U. Subrahmanyeswara Rao

  2. Department of Pharmacy Practice, Appalachian College of Pharmacy, Oakwood, VA, 24631, USA

    Susan L. Mayhew

  3. Department of Pathology, Covenant Health System, Lubbock, TX, 79430, USA

    Seshadri Thirumala

Authors
  1. Prema S. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morgan Labhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan L. Mayhew
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seshadri Thirumala
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Subrahmanyeswara Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Subrahmanyeswara Rao.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rao, P.S., Labhart, M., Mayhew, S.L. et al. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain. Tumor Biol. 35, 7267–7273 (2014). https://doi.org/10.1007/s13277-014-1979-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1979-9

Keywords

Search

Navigation